Directive transparence : information réglementée

03/06/2015 08:00
DGAP-News: Neovacs S.A. / Key word(s): Conference NEOVACS TO PRESENT AT 2015 BIO INTERNATIONAL CONVENTION 03.06.2015 / 08:00 --------------------------------------------------------------------- NEOVACS TO PRESENT AT 2015 BIO INTERNATIONAL CONVENTION Company to Highlight Active Immunotherapy Platform Focused on Autoimmune Diseases and Cancer Paris and Boston, June 3, 2015 - NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases and solid tumors, announced today that it has been selected to present at the 2015 BIO International Convention to be held in Philadelphia, June 15-18, 2015. Neovacs has strengthened its position in the U.S. since 2014, notably with: - The installation of its Scientific Advisory Board in New York City; - The creation of a U.S. subsidiary, Neovacs, Inc, in Boston; - The preparation of U.S.-based clinical trials with IFN?-Kinoid; - Participation in key U.S. investor conferences Neovacs' participation at BIO 2015 corresponds with these U.S. expansion efforts. Neovacs will have its own booth within the French Pavillion* where CEO Miguel Sieler will present recent information on the Company's proprietary active immunotherapy platform for the treatment of auto-immune diseases and solid tumors on Tues., June 16 at 4:15 p.m. EDT. BIO International Convention is the world's largest biotechnology convention, gathering several thousand companies from the global biotechnology and pharmaceutical industry. More information on BIO 2015 is available at http://convention.bio.org/2015/. * http://convention.bio.org/pavilions/ About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN?-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, please visit www.neovacs.fr Contacts NEOVACS - Investor Relations Nathalie Trépo +33 (0)1 53 10 93 00 ntrepo@neovacs.com Investor Relations / Financial Communications - NewCap Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 neovacs@newcap.fr Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-210228-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Melanie Sollid-Penton 1.646.536.7023 msollid@theruthgroup.com --------------------------------------------------------------------- 03.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News-Service --------------------------------------------------------------------- 364743 03.06.2015